uniQure to Participate at Multiple Upcoming Conferences
August 30 2018 - 6:00AM
uniQure to Participate at Multiple Upcoming Conferences
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that it will participate in the following
upcoming conferences in September:
• Wells Fargo Securities 2018 Healthcare Conference,
September 5 – 6, 2018 at the Westin Copley Place in Boston,
MA.
- Matt Kapusta, chief executive officer at uniQure, will present
a corporate update on Wednesday, September 5th at 3:35 p.m. ET. The
live webcast can be accessed through the link displayed in the
Investor section of the uniQure website. The webcast replay will be
available for at least 72 hours following the live event.
- In addition, company management will host meetings with
institutional investors.
• Citi’s 13th Annual Biotech Conference, September
5 – 6, 2018 at the Four Seasons Hotel in Boston, MA.
- Matt Kapusta will participate in a panel discussion entitled,
“Gene Therapy: Present & Future”, moderated by Citi analysts,
on Thursday, September 6th at 10:00 a.m. ET. The live webcast can
be accessed through the link displayed in the Investor section of
the uniQure website. The webcast replay will be available for at
least 72 hours following the live event.
- In addition, company management will host meetings with
institutional investors.
• Goldman Sachs 8th Annual Biotech Symposium,
September 7, 2018 at Goldman Sachs London Offices, in London,
United Kingdom.
- Sander van Deventer, M.D., Ph.D., chief scientific officer at
uniQure, will be available for one-on-one meetings with
institutional investors on Friday, September 7th.
• 2018 Janney Healthcare Conference, September 17,
2018 at the Union League Club in New York City.
- Sander van Deventer, M.D., Ph.D., chief scientific officer,
will present a corporate update on Monday, September 17th at 10:45
a.m. ET.
- In addition, company management will host meetings with
institutional investors.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
liver/metabolic, central nervous system and cardiovascular
diseases. www.uniQure.com
uniQure Contacts
For Investors: |
|
|
|
For Media: |
|
|
|
|
|
|
|
|
|
Maria E. Cantor |
|
Eva M. Mulder |
|
Tom Malone |
|
|
Direct: 339-970-7536 |
|
Direct: +31 20 240 6103 |
|
Direct: 339-970-7558 |
|
|
Mobile: 617-680-9452 |
|
Mobile: +31 6 52 33 15 79 |
|
Mobile: 339-223-8541 |
|
|
m.cantor@uniQure.com |
|
e.mulder@uniQure.com |
|
t.malone@uniQure.com |
|
|
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2024 to May 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From May 2023 to May 2024